Pfizer and biontech receive positive chmp opinion for omicron kp.2-adapted covid-19 vaccine in the european union

New york & mainz, germany--(business wire)--pfizer inc. (nyse: pfe, “pfizer”) and biontech se (nasdaq: bntx, “biontech”) today announced that the committee for medicinal products for human use (chmp) of the european medicines agency (ema) has recommended marketing authorization for the companies' omicron kp.2-adapted monovalent covid-19 vaccine (comirnaty® kp.2) for active immunization to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. the european commission wil.
BNTX Ratings Summary
BNTX Quant Ranking